Home › Funds › Palo Alto Investors LP › NBIX

Palo Alto Investors LP position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Palo Alto Investors LP reported holding 18,117 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 0.38% of its reported portfolio and ranking #34 among its reported holdings. Palo Alto Investors LP has disclosed NBIX holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)18.12K sh
Reported value held$2.57M
Portfolio Weight0.38%
First reportedQ1 2025
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Palo Alto Investors LP's NBIX position evolved

Palo Alto Investors LP first disclosed a stake in NBIX in Q1 2025 at 13,334 shares (US$1.5M). The position peaked in Q2 2026 at 18,117 shares, worth US$3.1M. Across 7 filings, Palo Alto Investors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 18,117 shares valued at US$2.6M. Notable position changes include a 36% increase in Q3 2025 (shares rose 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 13.33K $1.47M New
Q2 2025 13.33K $1.68M Hold
Q3 2025 18.12K $2.54M Add
Q4 2025 18.12K $2.57M Hold
Q1 2026 18.12K $2.39M Hold
Q2 2026 18.12K $3.05M Hold
Q3 2026 18.12K $2.57M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 28 other funds we track also report a position in NBIX — the largest reported positions include Vestal Point Capital, LP (US$354.6M), Renaissance Technologies (US$326.3M), RTW INVESTMENTS, LP (US$133.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Palo Alto Investors LP held NBIX?

Palo Alto Investors LP has disclosed NBIX holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is Palo Alto Investors LP's current position in NBIX?

As of Q3 2026, Palo Alto Investors LP holds 18.12K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $2.57M, representing 0.38% of its reported portfolio and ranking #34.

Has Palo Alto Investors LP been buying or selling NBIX?

In the latest 13F filing (Q3 2026), Palo Alto Investors LP held unchanged its position in NBIX. The position peaked in Q2 2026 at 18.12K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Vestal Point Capital, LP, Renaissance Technologies, RTW INVESTMENTS, LP, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.